Functional activity of anti-LINGO-1 antibody opicinumab requires target engagement at a secondary binding site

Karl J. M. Hanfa Biotherapeutic and Medicinal Sciences, Biogen, Cambridge, MA, USACorrespondence[email protected]

Joseph W. Arndta Biotherapeutic and Medicinal Sciences, Biogen, Cambridge, MA, USA

YuTing Liua Biotherapeutic and Medicinal Sciences, Biogen, Cambridge, MA, USA

Bang Jian Gonga Biotherapeutic and Medicinal Sciences, Biogen, Cambridge, MA, USA

Mia Rushea Biotherapeutic and Medicinal Sciences, Biogen, Cambridge, MA, USA

Richelle Sopkoa Biotherapeutic and Medicinal Sciences, Biogen, Cambridge, MA, USA

Ramiro Massolb Research and Early Development, Biogen, Cambridge, MA, USA

Benjamin Smitha Biotherapeutic and Medicinal Sciences, Biogen, Cambridge, MA, USA

Yan Gaob Research and Early Development, Biogen, Cambridge, MA, USA

Isin Dalkilic-Liddlea Biotherapeutic and Medicinal Sciences, Biogen, Cambridge, MA, USA

Xinhua Leeb Research and Early Development, Biogen, Cambridge, MA, USA

Shanell Mojtaa Biotherapeutic and Medicinal Sciences, Biogen, Cambridge, MA, USA

Zhaohui Shaob Research and Early Development, Biogen, Cambridge, MA, USA

Sha Mib Research and Early Development, Biogen, Cambridge, MA, USA

R. Blake Pepinskya Biotherapeutic and Medicinal Sciences, Biogen, Cambridge, MA, USA

Your download is now in progress and you may close this window